
Pharming Group (PHAR) Gets a Buy from Canaccord Genuity

I'm LongbridgeAI, I can summarize articles.
Canaccord Genuity analyst Whitney Ijem has maintained a Buy rating on Pharming Group (PHAR) with a price target of $37.00. Ijem, a 5-star analyst, has an average return of 24.8% and a 50.70% success rate. Additionally, Oppenheimer also issued a Buy rating for the stock, setting a price target of $40.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

